Compugen Ltd. · NASDAQ:CGEN

Compugen — Investor Presentation (June 2016)

47 slides from Compugen's investor presentation, June 2016

  1. Slide 1: Predictive Discovery of First-in-Class Biologics

    PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS Primary focus on immuno-oncology Corporate Overview June 2016 www.cgen.com www.cgen.com 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” and “intends,”

  3. Slide 3: Company Overview

    Company Overview  Mission Discover high value novel targets and develop first-in-class biologics for unmet medical needs  Leadership in Predictive Drug Discovery Broadly applicable discovery infrastructure  Business Model Selectively partner first-in-class biologics at various stages under revenu

  4. Slide 4: Company Fact Sheet

    Company Fact Sheet  Strong Intellectual Property Landscape  Proprietary algorithms and computational biology platforms  61 issued and allowed patents, 137 pending patent applications, in all major countries  Experienced Multidisciplinary Teams  ~90 employees, 70% R&D  Algorithm development, co

  5. Slide 5: Two Centers of Excellence

    Two Centers of Excellence Compugen Ltd. Compugen USA, Inc. Holon, Israel South San Francisco, USA Headquarters Wholly-Owned Subsidiary Predictive Target Discovery Therapeutic mAb & Experimental Validation Research & Development 5

  6. Slide 6: Scientific Advisory Board

    Scientific Advisory Board Renowned Oncologists and Immunologists  Drew Pardoll, MD, PhD (Chairman of the SAB; Director - Compugen USA, Inc.) Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the

  7. Slide 7: Pipeline Program Focus Areas

    Pipeline Program Focus Areas Multiple Novel Target Candidates for First-in-Class Opportunities Oncology Novel Novel immune checkpoint Antibody Drug Conjugate target candidates target candidates Immunology One program for autoimmune diseases based on a novel immune checkpoint target Diverse portfolio

  8. Slide 8: B7/CD28 Immune Checkpoints for Cancer Immunotherapy

    B7/CD28 Immune Checkpoints for Cancer Immunotherapy  Harnessing the immune system to destroy cancer cells  Breakthrough approach to cancer therapy  Impressive, long-lasting clinical benefits  Still, the majority of cancer patients do not respond  New checkpoints, drug combinations and drug moda

  9. Slide 9: Targeting of Immune Checkpoints Today

    Targeting of Immune Checkpoints Today Crowded Competition on Same Targets PI PIII PC PIII PII PI PC ? M M PC PII PI PC PC PI PI M PI PC PC PI PII PI PC PC PC PI PC PC PI PC PC PC PC PC PC

  10. Slide 10: From the Genome to the Clinic

    From the Genome to the Clinic An Integrated Approach PREDICTIVE PIPELINE STRATEGIC PREDICTIVE DISCOVERY PROGRAM PARTNERSHIPS DISCOVERY 10

  11. Slide 11: Pharma's Observational Path to Novel Targets

    Pharma’s Observational Path to Novel Targets COLLECTION OF DISEASE KNOWN GENES / PROTEINS SAMPLES EXPERIMENTAL CHARACTERIZATION DATA ANALYSIS NOVEL TARGETS FIRST-IN-CLASS Known proteins/genes, disease-specific, assay systems limitation No learning

  12. Slide 12: Compugen: Leaders in Predictive Biology

    Compugen: Leaders in Predictive Biology Merging Computational Biology and Translational Medicine 15 YEARS OF SCIENTIFIC INFRASTRUCTURE DEVELOPMENT Broadly applicable, consists of multiple discovery platforms APPLIED TO DISCOVERY OF NOVEL DRUG TARGET FOR FIRST-IN-CLASS BIOLOGICS

  13. Slide 13: Applying Our Predictive Approach

    Applying Our Predictive Approach First Focused Discovery Program: Novel Immune Checkpoint Targets CGEN-15001T CGEN-15052 CGEN-15022 CGEN-15092 CGEN-15049 CGEN - 15029 Undisclosed Targets Partial data sources shown for illustrative purposes B7 refers to B7/CD28 13

  14. Slide 14: Immune Checkpoint Platform

    Immune Checkpoint Platform Genomic Detection Leading to Diverse Set of Novel Candidates Diversified portfolio of immuno-oncology targets CGEN candidate Shown for illustrative purpose only 14

  15. Slide 15: From the Genome to the Clinic

    From the Genome to the Clinic An Integrated Approach PREDICTIVE PIPELINE STRATEGIC PIPELINE DISCOVERY PROGRAM PARTNERSHIPS PROGRAM 15

  16. Slide 16: Pipeline Program

    Pipeline Program Novel Immune Checkpoint Target Candidates CGEN-15029 Lead drug program Shown for illustrative purpose only 16

  17. Slide 17: CGEN-15029 mRNA is Expressed in Many Cancers

    CGEN-15029 mRNA is Expressed in Many Cancers Expression in multiple cancer indications Elevated expression in kidney cancers 17

  18. Slide 18: CGEN-15029 Expression Associated With Tumor Infiltrating Immune Cells

    CGEN-15029 Expression Pattern Associated With Tumor Infiltrating Immune Cells (TILs) RNA correlation with CD8 T cells and PD-1 Confirmed TIL protein expression (Kidney Clear Cell Cancer) (Melanoma) CD8 vs 15029 PD-1 vs 15029 18

  19. Slide 19: RNA Expression of CGEN-15029 Correlated With PD-1, TIM-3 and TIGIT

    RNA Expression of CGEN-15029 Highly Correlated With PD-1, TIM-3 and TIGIT in Solid Tumors All tumors (TCGA) Melanoma (TCGA) 19

  20. Slide 20: CGEN-15029 Expressed on Tumor Infiltrating T-cells from Melanoma Patients

    CGEN-15029 Expressed on Tumor Infiltrating T-cells Derived from Melanoma Patients TIL Patient 1 TIL Patient 2 CGEN-15029 KD + anti 15029 CGEN-15029 Negative Control (hIgG2) Expression is confirmed by knockdown (siRNA)

  21. Slide 21: CGEN-15029 Inhibits T Cell Cytotoxic Activity

    CGEN-15029 Inhibits T Cell Cytotoxic Activity Inhibition of Cytotoxic T Cell Activation Cohen and Safion, Bar Ilan Univ. 21

  22. Slide 22: CGEN-15029: Binding Partner Identified

    CGEN-15029: Binding Partner Identified Binding of hCGEN-15139-Fc to HEK293 cells over expressing hCGEN-15029 Binding of ligand (CGEN-15139) to receptor (CGEN-15029) was confirmed by SPR, ELISA and FACS 22

  23. Slide 23: COM701 Lead mAb Demonstrates High Affinity Binding

    COM701 Lead mAb Demonstrates High Affinity Binding Sub-nanomolar affinity binding to T cell line 23

  24. Slide 24: COM701 Lead mAb Potently Inhibits Receptor-Ligand Interactions

    COM701 Lead mAb Potently Inhibits Receptor - Ligand Interactions Antibody binding and activity maintained following humanization Potent enhancement of T cell activation 24

  25. Slide 25: CGEN-15029: Highest Priority mAb Program

    CGEN-15029: Highest Priority mAb Program  High-affinity functional blocking antibodies have been identified  Lead therapeutic mAb selected – COM71  Humanization process completed  Cell line development initiated  Manufacturing agreement in place  IND anticipated in 2017 25

  26. Slide 26: Pipeline Program

    Pipeline Program Novel Immune Checkpoint Target Candidates CGEN-15029 Lead drug program CGEN candidate Shown for illustrative purpose only 26

  27. Slide 27: Myeloid CGEN-Candidates

    Myeloid CGEN-Candidates Myeloid cells are important components of the tumor microenvironment Primarily Tumor Associated Macrophages (TAMs) and Myeloid Derived Suppressor Cells (MDSCs) TAMs and MDSCs are highly immunosuppressive and inhibit effector T and NK responses against the tumors Emerging area

  28. Slide 28: Myeloid CGEN-Candidate

    Myeloid CGEN-Candidate Low Expression in Solid Normal Tissues and Induction in Cancer CGEN-Candidate Expression Profile in CGEN-Candidate Expression Normal Tissues Normal vs. Cancer 28

  29. Slide 29: Myeloid CGEN-Candidate: CD68 Expression

    Myeloid CGEN-Candidate Induction in Cancer Correlated with Myeloid Specific Markers CD68 Expression Myeloid CGEN Candidate Expression 29

  30. Slide 30: CGEN-Candidates Expressed in Specific Myeloid Subpopulations

    CGEN-Candidates Expressed in Specific Myeloid Subpopulations Example 1 Macrophage Naïve Immune Cells Lung Tumor Subpopulations 30

  31. Slide 31: CGEN-Candidates Expressed in Specific Myeloid Subpopulations

    CGEN-Candidates Expressed in Specific Myeloid Subpopulations Example 2 Macrophage Naïve Immune Cells Lung Tumor Subpopulations 31

  32. Slide 32: Pipeline Program

    Pipeline Program Novel Immune Checkpoint Target Candidates CGEN candidate • Two partnered I/O programs • Fc-fusion for autoimmune diseases Shown for illustrative purpose only 32

  33. Slide 33: Cell Surface Tumor Antigen Targets

    Cell Surface Tumor Antigen Targets Second Focused Discovery Program: ADC Targets The goal: identify membrane proteins over-expressed on cancer but with little or no expression on normal tissues 33

  34. Slide 34: Example: Expression Profile Analysis

    Example: Expression Profile Analysis High Cancer Expression, Low Toxicity, Low Sink Potential Predictive discovery driven analysis 34

  35. Slide 35: CGEN-15027: A Novel ADC Target

    CGEN-15027: A Novel ADC Target High Expression in Ovarian and Lung Cancers Normal Ovary Ovarian Cancer Ovarian Cancer (Endometroid adenocar.) (Mucinous cystadenocar.) Normal Lung Lung Cancer Lung Cancer (Adenocarcinoma.) (Adenocarcinoma) 35

  36. Slide 36: Antibody-Drug Conjugate Against CGEN-15027

    Antibody-Drug Conjugate Against CGEN-15027 Potent Cytotoxicity in Multiple Cancer Cell Lines FACS Cytotoxicity Binding IHC Ovarian Adenocarcinoma Cell line IC50= 0.18 Liver HCC Cell line IC50= 0.078

  37. Slide 37: CGEN-15001: Lead Program for Autoimmune Diseases

    CGEN-15001: Lead Program for Autoimmune Diseases Robust Efficacy in Animal Models EAE: Multiple Sclerosis CIA: Rheumatoid Arthritis NOD: Type 1 Diabetes Rx Rx Miller and Podojil, Northwestern Univ. Williams and McNamee, Univ. of Oxford, UK Miller and Podojil, Northwestern Univ. HY Mismatch: Bone Mar

  38. Slide 38: CGEN-15001 Differentiation and Value Proposition

    CGEN-15001 Differentiation and Value Proposition Differentiating Features from Current Therapies • Restores immune balance • Inhibits pro-inflammatory and promotes anti-inflammatory cytokines • Restores the Th1/Th2/Treg balance – promotes iTreg differentiation • Induces antigen-specific immune toler

  39. Slide 39: From the Genome to the Clinic

    From the Genome to the Clinic An Integrated Approach PREDICTIVE PIPELINE STRATEGIC STRATEGIC DISCOVERY PROGRAM PARTNERSHIP PARTNERSHIPS 39

  40. Slide 40: Strategic Alliances to Drive Value

    Strategic Novel Alliances to Drive Value Targets for First-in-Class and Opportunities Commercialize The Next Wave Programs in Immuno-Oncology  Multiple programs to be advanced through combination of internal development and collaborations  Enter collaborations at both early and later stage of deve

  41. Slide 41: Bayer Novel Partnership

    BayerNovel Partnership Targets for First-in-Class Opportunities Strategic TheCollaboration Next WavetoinDevelop Cancer Immunotherapies Immuno-Oncology Early stage collaboration and license agreement for antibody-based cancer therapeutics  Collaboration includes two novel immune checkpoint target ca

  42. Slide 42: Bayer Novel Partnership: Current Status

    BayerNovel Partnership: Current Status Targets for First-in-Class Opportunities The Next Next Targets Wave in Immuno-Oncology for Anti-Tumor Immunity • CGEN-15001T and CGEN-15022: Two novel immune checkpoints • Each presents a distinctive differentiation profile compared to known checkpoints • Targe

  43. Slide 43: Collaboration with Johns Hopkins School of Medicine

    Collaboration with Johns Hopkins School of Medicine Multi-Year Immuno-Oncology Collaboration • Focused on Compugen’s novel immune checkpoint target candidates • Led by Johns Hopkins Professors Drew Pardoll and Charles Drake • Supports and accelerates translation to the clinic • Target characterizati

  44. Slide 44: From the Genome to the Clinic: Drivers and Anticipated Milestones

    From the Genome to the Clinic Drivers and Anticipated Milestones  hPOC in clinical trials: Partnered and un-partnered programs  Advancing internal programs  First IND anticipated in 2017 for CGEN-15029  Multiple programs in various stages of target validation or antibody discovery Continuing pro

  45. Slide 45: Financial Status

    Financial Status • Strong Financial position • Cash balance ~$81 million (March 31, 2016) • No Debt • Gross Cash Expenditures* • Forecast 2016 ~$31-$33 million • Market Capitalization • ~$350 million (May 2016) • NASDAQ (CGEN); Indices – NBI (Nasdaq Biotech Index) • TASE (CGEN.TA); Indices - TA-75,

  46. Slide 46: Compugen's Key Differentiators

    Compugen’s Key Differentiators  Focus on First-in-Class Therapeutics  Pipeline Program based on novel targets  Significant opportunity for first-in-class drugs  Broad IP landscape  Reliance on Predictive Discovery  Discover multiple target candidates for each discovery program  Predict new li

  47. Slide 47: Predictive Discovery of First-in-Class Biologics

    PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS Primary focus on immuno-oncology Corporate Overview June 2016 www.cgen.com www.cgen.com

Compugen — Investor Presentation (June 2016) on 6ix